Category: 637-58-1

Vincent, Andrea published the artcileIdentification of candidate drugs for the treatment of ALS, Related Products of ethers-buliding-blocks, the publication is Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders (2005), 6(1), 29-36, database is CAplus and MEDLINE.

A consortium of investigators interested in neurodegenerative diseases collaborated to screen 1040 drugs in multiple neurodegenerative disease assays. One model of amyotrophic lateral sclerosis (ALS) pathogenesis in particular incorporated glutamate exposure in enriched primary rat motor neuron cultures. In this model 78 compounds decreased motor neuron death caused by 100 μM glutamate. Almost all these pharmacol. agents act at one or more of the following cellular targets: (1) protein synthesis inhibition; (2) Cox inhibition; (3) regulation of anion flux; (4) modulation of GABA receptors; (5) antioxidant, and (6) cell cycle inhibition. The most prevalent mode of action was the regulation of intracellular calcium. These data extend the understanding of motor neuron degeneration and identify a number of cellular targets for the improvement of combined therapies for neurodegenerative disease.

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C42H63O3P, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Pottel, Joshua published the artcileThe activities of drug inactive ingredients on biological targets, Related Products of ethers-buliding-blocks, the publication is Science (Washington, DC, United States) (2020), 369(6502), 403-413, database is CAplus and MEDLINE.

Excipients, considered “inactive ingredients,” are a major component of formulated drugs and play key roles in their pharmacokinetics. Despite their pervasiveness, whether they are active on any targets has not been systematically explored. We computed the likelihood that approved excipients would bind to mol. targets. Testing in vitro revealed 25 excipient activities, ranging from low-nanomolar to high-micromolar concentration Another 109 activities were identified by testing against clin. safety targets. In cellular models, five excipients had fingerprints predictive of system-level toxicity. Exposures of seven excipients were investigated, and in certain populations, two of these may reach levels of in vitro target potency, including brain and gut exposure of thimerosal and its major metabolite, which had dopamine D3 receptor dissociation constant K_d values of 320 and 210 nM, resp. Although most excipients deserve their status as inert, many approved excipients may directly modulate physiol. relevant targets.

Science (Washington, DC, United States) published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem